Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 3/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.34 |
| ▸ | F12 | P00748 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075466 | 0.81 | STS (0.42) | RORCSTSGPR119 | |
| SCHEMBL2076671 | 0.78 | ADORA1 (0.37) | ADORA1USP2SMN1; SMN2STSGPR119 | |
| SCHEMBL4192572 | 0.75 | CCNA2 (0.39) | ADORA1USP2SMN1; SMN2STSGPR119 | |
| SCHEMBL16037196 | 0.75 | ADORA1 (0.35) | RORCADORA1GPR119F12ESR2 | |
| SCHEMBL29689494 | 0.75 | ADORA1 (0.41) | ADORA1F12PARP1TNKS2PARP2 | |
| SCHEMBL2073728 | 0.75 | ADORA1 (0.36) | ADORA1USP2SMN1; SMN2STSGPR119 | |
| SCHEMBL16033804 | 0.74 | ADORA1 (0.40) | ADORA1GPR119PARP1TNKS2PARP2 | |
| SCHEMBL22011297 | 0.74 | PARP1 (0.41) | ADORA1GPR119F12PARP1TNKS2 | |
| SCHEMBL30776238 | 0.74 | PARP1 (0.41) | ADORA1GPR119F12PARP1TNKS2 | |
| SCHEMBL2075868 | 0.74 | ADORA1 (0.36) | ADORA1USP2SMN1; SMN2STSGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560927-B1 | AZEPINE DERIVATIVES ACTING AS 5-HT7 RECEPTOR MODULATORS | KOREA INST SCI & TECH (KR) | 2023-04-19 | — | — | EP | disclosed |
| EP-3560927-A1 | AZEPINE DERIVATIVE ACTING AS 5-HT7 RECEPTOR MODULATOR | Korea Institute of Science and Technology (KR) | 2019-10-30 | — | — | EP | disclosed |
| US-10435408-B2 | Azepine derivatives as 5-HT7 receptor modulators | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2019-10-08 | — | — | US | disclosed |
| US-20180312509-A1 | AZEPINE DERIVATIVES AS 5-HT7 RECEPTOR MODULATORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312509-A1 | AZEPINE DERIVATIVES AS 5-HT7 RECEPTOR MODULATORS | HTR7, HTR5A, HTR3A | RORC 1569/4885ADORA1 156/4885USP2 2832/4885 |
| US-10435408-B2 | Azepine derivatives as 5-HT7 receptor modulators | HTR7, HTR5A, HTR3A | RORC 1569/4885ADORA1 156/4885USP2 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.